美托洛尔与曲美他嗪对冠心病舒张功能不全患者的干预研究Δ  

The Study of Trimetazidine and Metoprolol Treatment in Diastolic Dysfunction Patients with Coronary Ar- tery Disease

作　　者：田志[1] 梅霞[1] 王骄[1] 谢英[1] 

机构地区：[1]重庆市中山医院,重庆市400013

出　　处：《中国药房》2010年第36期3379-3381,共3页China Pharmacy

基　　金：重庆市卫生局科研资助项目(07-2-230)

摘　　要：目的:观察美托洛尔和曲美他嗪对冠心病舒张功能不全患者左心室舒张功能以及血清炎症因子水平的影响。方法:筛选137例冠心病左室舒张功能不全患者,随机分成曲美他嗪组、美托洛尔组、联合组(曲美他嗪联合美托洛尔),分别在入选和治疗12个月后检测心绞痛症状、心脏超声、脑钠肽(BNP)、C-反应蛋白(CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)。结果:联合组心绞痛治疗有效率(93.33%)较另2组高,但差异无统计学意义(P>0.05)。3组患者治疗后心室舒张功能均明显改善(P<0.01);BNP显著减少(P<0.01);炎症因子CRPI、L-6、TNF-α无明显改善(P>0.05)。结论:曲美他嗪和美托洛尔长期治疗后都能有效改善冠心病患者临床症状以及左室舒张功能;未发现2种药物对炎症因子有意义的影响。OBJECTIVE：To observe the change of left ventricular diastolic function and serum inflammatory factors after trimetazidine（TMZ）and metoprolol treatment in patients with coronary artery disease.METHODS：137 cases were randomly divided into TMZ group、metoprolol group and joint group（trimetazidine combined with metoprolol）,we evaluated the angina pectoris、 ultra cardiogram、BNP、CRP、IL6、TNFα before treatment and after treatment（after 1 year.） RESULTS：The effective rate（93.33%）of angina pectoris in joint group was higher than others（P0.05.）In all groups,left vertricular diastolic function was significantly upgraded（P0.01）;BNP was significantly decreased（P0.01）s;erum inflammatory factors CRPI、L6、TNFα were not significantly changed（P0.05.）CONCLUSION：TMZ and metoprolol treatment can effectively improve clinical symptom and left ventricular diastolic function of coronary artery patients;They did not improve serum inflammatory factors of coronary artery patients significantly.

关 键 词：冠状动脉疾病 舒张功能不全 炎症因子 曲美他嗪 美托洛尔 

分 类 号：R917[医药卫生—药物分析学]